Type 2 cannabinoid receptor expression on microglial cells regulates neuroinflammation during graft-versus-host disease
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci175205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Alison Moe und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine. Hauptthemen laut MEDLINE: Graft vs Host Disease, Microglia, Neuroinflammatory Diseases, Receptor, Cannabinoid, CB2. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Neuroinflammation is a recognized complication of immunotherapeutic approaches such as immune checkpoint inhibitor treatment, chimeric antigen receptor therapy, and graft versus host disease (GVHD) occurring after allogeneic hematopoietic stem cell transplantation. While T cells and inflammatory cytokines play a role in this process, the precise interplay between the adaptive and innate arms of the immune system that propagates inflammation in the central nervous system remains incompletely understood. Using a murine model of GVHD, we demonstrate that type 2 cannabinoid receptor (CB2R) signaling plays a critical role in the pathophysiology of neuroinflammation. In these studies, we identify that CB2R expression on microglial cells induces an activated inflammatory phenotype that potentiates the accumulation of donor-derived proinflammatory T cells, regulates chemokine gene regulatory networks, and promotes neuronal cell death. Pharmacological targeting of this receptor with a brain penetrant CB2R inverse agonist/antagonist selectively reduces neuroinflammation without deleteriously affecting systemic GVHD severity. Thus, these findings delineate a therapeutically targetable neuroinflammatory pathway and have implications for the attenuation of neurotoxicity after GVHD and potentially other T cell–based immunotherapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine.
- Department of Pharmacology, and.
- Division of Biostatistics, Institute of Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- College of Pharmacy, Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
- Department of Pathology and Immunology, Washington University, Saint Louis, Missouri, USA.
- Department of Pathology, Northwestern University, Chicago, Illinois, USA.
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- Minesterio de Ciencia e Innovacion/Agencia Estatal de Investigacion
Zitieren
APA
Moe, A., Rayasam, A., Sauber, G., Shah, R. K., Doherty, A., Yuan, C. Y., Szabo, A., Moore, B. M., Colonna, M., Cui, W., Romero, J., Zamora, A. E., Hillard, C. J., & Drobyski, W. R. (2024). Type 2 cannabinoid receptor expression on microglial cells regulates neuroinflammation during graft-versus-host disease. Journal of Clinical Investigation. https://doi.org/10.1172/jci175205
Vancouver
Moe A, Rayasam A, Sauber G, Shah RK, Doherty A, Yuan CY, et al. Type 2 cannabinoid receptor expression on microglial cells regulates neuroinflammation during graft-versus-host disease. Journal of Clinical Investigation. 2024. doi:10.1172/jci175205
BibTeX
@article{Moe2024,
author = {Moe, Alison and Rayasam, Aditya and Sauber, Garrett and Shah, Ravi K and Doherty, Ashley and Yuan, Cheng-Yin and Szabo, Aniko and Moore, Bob M and Colonna, Marco and Cui, Weiguo and Romero, Julian and Zamora, Anthony E and Hillard, Cecilia J and Drobyski, William R},
title = {Type 2 cannabinoid receptor expression on microglial cells regulates neuroinflammation during graft-versus-host disease},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci175205}
}
EUVIMED